Sign in
Enrolling by invitationNo phase

Tracks safety of Zyprexa Relprevv injections in people with schizophrenia

Observes safety monitoring for Zyprexa Relprevv injections in adults with schizophrenia.

Key facts

Who runs it
Eli Lilly and Company
Where
Blue Bell, United StatesSee the site
Trial code
Registry title
Zyprexa® Relprevv™ Patient Care Program
Status
Enrolling by invitation
People taking part
4,000 people, planned
Started
3 Mar 2010
Planned end
Jun 2026
Type of study
Observational
Record updated
28 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The program is for adults with schizophrenia who are receiving Zyprexa Relprevv. It aims to lower the risk of problems from post-injection delirium/sedation syndrome (PDSS).

Age
18 Years and older
Sex
All sexes can join.
Earlier treatment
People must be receiving Zyprexa Relprevv and be enrolled in the Zyprexa Relprevv Patient Care Program.

Main reasons for not taking part

  • Anyone not receiving Zyprexa Relprevv cannot join.

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Any patients receiving Zyprexa Relprevv enrolled in Zyprexa Relprevv Patient Care Program

Who cannot take part

  • Any patient not receiving Zyprexa Relprevv

Where in United States

  • United BioSource CorporationBlue Bell, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

The goal of the Zyprexa Relprevv Patient Care Program is to mitigate the risk of negative outcomes associated with Zyprexa Relprevv post-injection delirium/sedation syndrome (PDSS).

The group in the trial

  • Patients

    All patients who will be receiving Zyprexa Relprevv must be enrolled into the Zyprexa Relprevv Patient Care Program

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Zyprexa® Relprevv™ Patient Care Program
Plain-language title
Tracks safety of Zyprexa Relprevv injections in people with schizophreniaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
28 January 2026